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ORIGINAL RESEARCH
ERECTILE DYSFUNCTION
A Retrospective Study of Erectile Function and Use of Erectile Aids in
Prostate Cancer Patients After Radical Prostatectomy in Denmark
Martha Kirstine Haahr, MD,1,2 Nessn H. Azawi, MD, PhD,1,2,3 Line Grønbaek Andersen,2 Steen Carlson, MD,1 and
Lars Lund, MD, PhD1,2
ABSTRACT
Introduction: Radical prostatectomy (RP) offers a good long-term cancer control for clinically localized prostate
cancer. However, complications such as erectile dysfunction and substantial decreases quality of life of the
afﬂicted men and their sexual partners. Identiﬁcation of pre-, per-, and postoperative factors that correlate with
poor postoperative erectile status must be considered an important step to improving penile rehabilitation.
Aim: To describe postoperative erectile function after RP in a Danish cohort.
Methods: The medical records of 1,127 patients undergoing RP from March 2003 through September 2014
were reviewed retrospectively with a 12-month follow-up after surgery. In all, 704 patients fulﬁlling the inclusion
criteria were included in the ﬁnal analysis. Recovery was deﬁned as self-reported erection sufﬁcient for intercourse
(ESI) with or without usage of erectile aids.
Main Outcome Measures: Subjective reporting of erectile function and usage erectile aids 12 months after RP.
Results: ESI with or without erectile aids was reported by 226 men (32.1%), among whom 109 (48.2%)
required erectile aids. Erectile dysfunction (ED) was reported by 478 men (67.9%) and by 121 (25.3%) despite
use of erectile aids. Of men with ED, 155 (22%) stated not being interested in penile rehabilitation, 26 (3.7%)
stated not having resumed their sex life 12 months after RP, and 241 (34.2%) had ED and were unsatisﬁed with
the condition. We found that 134 of 445 men (30.1%) who underwent nonenerve-sparing RP had ESI 12
months after RP. Age older than 60.5 years, a high body mass index, comorbidity, and a high American Society
of Anesthesiologists score were negative predictors of erectile function 12 months after RP.
Conclusion: Twelve months after RP, 32.1% of men had ESI; half these men required the use of erectile aids.
Age older than 60.5 years, a high body mass index, comorbidity, and a high American Society of Anesthesiol-
ogists score were negative predictors for ED 12 months after RP. Haahr MK, Azawi NH, Andersen LG, et al.
A Retrospective Study of Erectile Function and Use of Erectile Aids in Prostate Cancer Patients After
Radical Prostatectomy in Denmark. Sex Med 2017;5:e156ee162.
Copyright  2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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INTRODUCTION
Prostate cancer (PCa) is the most commonly detected cancer
in men in developed countries, with nearly 800,000 new annual
cases, of which 325,000 occur in Europe.1 PCa is the most
common male malignancy in Denmark, with an incidence of
4,577 in 2014.2 In Denmark, PCa has followed an increasing
trend during the past decade, increasing by 35%, and the 2025
prevalence is expected to reach 90,000 cases.2
Radical prostatectomy (RP) or radiation therapy is the curative
treatment option recommended for patients with localized dis-
ease. RP offers good long-term cancer control for clinically
localized PCa,3 and the nerve-sparing technique is the treatment
of choice for localized PCa in sexually active men.4 Complica-
tions such as erectile dysfunction (ED) are feared by all men
undergoing RP because of its effects on the quality of life for the
man and his partner.5
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Other side effects of RP include loss of ejaculate, penile
shortening, change of orgasmic feeling, alterations in body image,
stress incontinence, disturbances in partner relationships, and
various types of anxiety.6 Managing penile rehabilitation should
include sexual rehabilitation addressing these issues to help men
cope with and accept a different sexual life. Evaluation and
treatment should be informed by a patient’s motivation, expec-
tations, and physical and mental health.
Functional outcomes after RP reported in the literature vary
widely with respect to sexual function depending on study design,
extent of follow-up, choice of outcome, patient age, comorbidity,
perioperative erectile status, type of surgery, high- vs low-volume
centers, and the extent of appropriate penile rehabilitation.7e16
The highest erectile function (EF) recovery rates are reported
from single-center and single-surgeon series with a large number
of patients. Many studies have reported on populations that are
likely younger than what is seen in the community.17 This
patient selection bias generally serves only to enrich the popu-
lation and augment the data on EF recovery, and therefore it
seems reasonable to question whether the results can be extrap-
olated to the general population.7
The objective of the present study was to describe post-
operative EF after RP in a Danish cohort and to identify any
predicative factors for EF.
METHODS
Settings and Patients
Data from 1,127 consecutive patients diagnosed with PCa
who underwent RP from March 2003 through September 2014
at the Department of Urology in the Odense University Hospital
(Odense, Denmark) were collected retrospectively from patient
records and analyzed. The operations were classiﬁed according to
the Nordic Medico-Statistical Committee Classiﬁcation of Sur-
gical Procedures. To obtain data on the number and type of RPs
performed per year, a search was carried out for procedure codes
KEC00 (radical retropubic prostatectomy), KEC01 (percuta-
neous endoscopic RP), KEC10 (perineal RP), and KEC20
(transsacral RP). KEC01 includes laparoscopic and robotic RPs,
but they can be identiﬁed by the secondary code ZXC96 used for
robot-assisted procedures. All procedures also were coded
according to neurovascular bundle preservation. The department
would be classiﬁed as a low-volume center (1e29 RPs) in 2003
to 2007, a medium-volume center (30e53 RPs) in 2008 to
2009, a high-volume center (54e105 RPs) in 2010, and a very
high-volume center (>105 RPs per year) after 2010. Permission
to conduct the study was obtained from the Danish Data Pro-
tection Agency (ﬁle number 2008-58-0035) and the Danish
Health Authority (ﬁle number 3-3013-1347/1/) in accordance
with Danish legislation.
Exclusion Criteria
We excluded men who were referred to their hometown
hospital before a full 12-month postoperative check-up, who had
PCa relapse within a year, who died or were diagnosed with a
serious illness that caused interruption of their routine follow-
ups, and who reported ED before undergoing RP (Figure 1).
Medical Record Data
Pre- and postoperative variables were retrieved from the
patient records. The following variables were recorded: age,
prostate-speciﬁc antigen (PSA) level, smoking and intake of
alcohol, medication, body mass index (BMI), spinal problems,
comorbidity, American Society of Anesthesiologists (ASA)
classiﬁcation,18 type of surgery, Gleason score,19 pathologic
tumor (pT) stage and surgical margin status, postoperative cancer
control, and EF at 12 months. Information on preoperative
status was assessed by the International Index of Erectile
Functione5 or by direct questions. EF was categorized as
unknown, EF sufﬁcient for intercourse (ESI), and ED. The last
group included men who had not resumed their sex life, men
who were not interested in penile rehabilitation, and sexually
active men who could not achieve ESI.
Statistical Methods
Descriptive data were analyzed using the c2 test and Fisher
exact test, and continuous variables were analyzed by t-test and
analysis of variance. Multivariate analysis was performed using
logistic regression in which ED and urinary incontinence were
the dependent variables and age, BMI, PSA, comorbidity,
surgical technique, pT stage, and Gleason score were the inde-
pendent variables. A P value less than .05 was considered sta-
tistically signiﬁcant. To select the threshold point of age related
to EF, the receiver-operating characteristics curve analysis was
used. Data are presented as mean and SD. Statistical analyses
were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
A total of 704 men with a median age of 62 years (SD ¼ 5.8)
and a median BMI of 26.7 kg/m2 (SD ¼ 3.2) were enrolled in the
study. Postoperative ED was seen in 478 men (67.9%) and ESI
was reported by 226 (32.1%). A normal BMI (<24.9 kg/m2) was
seen in 127 men (18.0%), 220 men (31.3%) were overweight
(BMI < 29.9), and 64 (9.9%) were obese (BMI> 30). In the ED
group, 345 men (72.2%) had a comorbidity of whom 208
(43.5%) had hypertension; in the ESI group, only 117 (51.8) had
a comorbidity of whom 66 (29.2%) had hypertension (Table 1).
We found a signiﬁcant difference between ASA scores of the ED
and ESI groups (P < .01; Table 1). In all, there were 119 smokers
(16.9%), and 105 men (18.7%) had an alcohol problem
(Table 1). Men in the ESI group were signiﬁcantly younger (mean
age ¼ 60 years; P < .01), had a lower prevalence of hypertension
(P < .05), and had a lower ASA score (P < .01) than men who
reported ED (Table 1).
There was no signiﬁcant difference (P < .13) in PSA between
the ED group (mean ¼ 10.6, SD ¼ 8.1) and the ESI group
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(mean ¼ 9.8, SD ¼ 6.2). Nerve-sparing RP (NSRP) was per-
formed in 259 patients (36.8%), among whom 74 (10.5%) had
unilateral nerve-sparing RP (UNSRP). The number of UNSRPs
performed was small, and we found no signiﬁcant difference in
ESI between UNSRP (36.5%) and bilateral NSRP (35.2%;
Table 2). All NSRPs were performed after 2010 and 92 men
(35.5%) in the NSRP group reported ESI 12 months after sur-
gery. We found that 134 of the 445 men (30.1%) who underwent
non-NSRP (NNSRP) had ESI 12 months after RP (Table 2).
Men in the ESI group had a lower Gleason score (P < .02) and
had undergone more extensive NSRP (P < .04; Table 2) than
men in the ED group. There was no signiﬁcant difference in
positive surgical margin between the two groups (P > .56).
Preoperative sexual function was stated in the patient record
in only 27 cases (3.9%), and 10 men (1.4%) used erectile
aids before RP. Overall, postoperative ED was reported by
478 men (67.9%).
The group of men reporting ED included 155 (22%) who
were not interested in penile rehabilitation and 26 (3.7%)
who stated that they had not resumed their sex life 12 months
after RP (Table 3). One third of men (241) stated being
sexually active but could not achieve ESI despite using erectile
aids or having tried erectile aids. Of these men, 36 (14.9%)
reported ED despite continuously using erectile aids (injection
therapy in 2.5%, phosphodiesterase type 5 inhibitor [PDE-5i]
in 12.5%); 91 (37.8%) had tried PDE-5i and 4 (1.7%) had
1,127 men underwent 
radical prostatectomy 
(2003-2014) 
797 (70.7%) paents had 
a full 12-month follow-up 
140 (12.4%) men were referred to their 
hometown hospital for follow-up directly aer  
RP 
13 (1.2%) died or were diagnosed with a serious 
illness which caused interrupon of roune follow-up 
95 (8.4%) men suﬀered prostate cancer relapse 
and were therefore excluded. 
*Excluded 
330 (29.3%) 
704 erecle funcon at 12-
month follow-up 
*Exclude
93 (11.7%) missing funconal 
status at 12-month follow-up 
94 (8.3%) suﬀered from erecle dysfuncon 
prior to RP 
Figure 1. Flowchart showing the inclusion process. RP ¼ radical prostatectomy.
Sex Med 2017;5:e156ee162
e158 Haahr et al
tried injection therapy (Table 3). Of men who reported being
sexually active but unable to achieve ESI, 117 (48.5%) were
referred for further sexual rehabilitation at their 12-month
follow-up (Table 3). Of men who reported erectile recovery,
108 (47.8%) used erectile aids (90 men [39.8%] used PDE-5i
and 18 men [8.4%] used injection therapy). Of men who
Table 1. Demographics and clinical data of the cohort*
Characteristics Total Erectile dysfunction
Erectile function sufﬁcient
for intercourse P value
Subjects 704 478 (67.9) 226 (32.1)
Patient age (y) 62 ± 5.8 63.2 ± 5.5 60 ± 5.9 <.01
Age < 63 y 387 230 157 <.0001
Age > 63 y 317 248 69
Body mass index (kg/m2) 26.7 ± 3.2 26.7 ± 3.2 27.0 ± 3.2 <.02
Not stated 293 (41.6) 189 (39.5) 104 (46)
Normal > 19 127 (30.9) 99 (34.3) 28 (23)
Overweight > 25 220 (53.5) 146 (50.5) 74 (60.7)
Obese > 30 64 (15.6) 44 (15.2) 20 (16.4)
Smoker 119 (19.3) 77 (18) 42 (22.1) .27
Alcohol overuse 105 (18.7) 70 (18) 35 (20.4) .07
Diabetes 27 (3.8) 22 (4.6) 5 (2.2) .15
Hypercholesterolemia 161 (22.9) 115 (24.1) 46 (20.4) .28
Hypertension 274 (38.9) 208 (43.5) 66 (29.2) <.05
ASA PS 1 273 (40.1) 166 107 (48.9) <.01
ASA PS 2 387 (56.9) 278 109 (49.8)
ASA PS 3 20 (2.9) 17 3 (1.4)
ASA PS not stated 24 (3.5) 17 (3.6) 7 (3.1)
ASA PS ¼ American Society of Anesthesiologists Physical Status.
*Data are presented as mean ± SD or number (percentage).
Table 2. Surgical and pathologic characteristics of cohort*
Characteristics Total Erectile dysfunction
Erectile function sufﬁcient
for intercourse P value
Subjects 704 478 (67.9) 226 (32.1)
Preoperative PSA (ng/mL) 10.0 ± 5.6 10.6 ± 8.1 9.8 ± 6.2 .13
Surgical approach
Open 524 (74.4) 353 (73.8) 171 (75.7)
RALP 180 (25.6) 125 (26.2) 55 (24.3) .64
Nerve-sparing status
None 445 (63.2) 346 (72.4) 134 (59.3)
Unilateral 74 (10.5) 35 (7.3) 27 (11.9) <.04
Bilateral 185 (26.3) 97 (20.3) 65 (28.8)
Pathologic tumor stage
T1eT2a 48 (6.8) 25 (5.24) 23 (10.2)
T2b 17 (2.4) 11 (2.3) 6 (2.7) .17
T2c 552 (78.4) 379 (79.3) 173 (76.5)
pT3a þ b 60 (8.5) 44 (9.2) 16 (7.1)
T3b 27 (3.8) 19 (4) 8 (3.5)
Gleason score
6 121 (17.1) 68 (14.3) 53 (23.5) <.02
3 þ 4 392 (55.7) 270 (56.5) 122 (54)
4 þ 3 148 (21.1) 111 (23.4) 37 (16.4)
8 28 (4) 18 (3.8) 10 (4.4)
9 15 (2.2) 11 (2.3) 4 (1.8)
Positive surgical margins 109 (15.5) 76 (10.8) 33 (14.6) .56
PSA ¼ prostate-speciﬁc antigen; RALP ¼ robot-assisted laparoscopic prostatectomy.
*Data are presented as mean ± SD or number (percentage).
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reported erectile recovery, 117 (51.8%) did not use erectile
aids (Table 3).
In univariate analysis, older age (P < .3) and PSA (P < .1)
showed no association with erectile outcome. In bivariate
analysis, hypertension (P < .0003), ASA score (P < .01),
NNSRP (P < .05), and Gleason score (P > .02) were signiﬁcant
predictors of a poor outcome for EF. Smoking, alcohol
overuse, pT stage, preoperative PSA, and surgical techniques
(robot-assisted vs open procedure) were not conﬁrmed as
signiﬁcant predictors of ED (P < .05). ESI showed a trend
(P < .09) toward improvement after 2010, when NSRP was
implemented. Patients no older than 60.5 years showed better
EF in the receiver-operating characteristics curve analysis.
In the multivariable analysis, age older than 60.5 years
(P < .01, 95% conﬁdence interval [CI] ¼ 0.14e1.08), a high
BMI (P < .01, 95% CI ¼ 0.79 to 0.08), a high ASA score
(P < .15, 95% CI ¼ 0.15e1.12), and NNSRP (P < .05,
95% CI ¼ 0.006e0.52) remained predictors of a poor outcome
for EF.
DISCUSSION
Our study showed that ESI was reported by 226 men (32.1%)
after RP, 117 (51.7%) of whom did not use erectile aids. Age,
BMI, NSRP, and ASA score were the most important factors
predicting a positive outcome. Another factor likely contributing
to the observed improvement was the volume of operations; the
number of patients receiving surgery increased from more than 50
per year before 2010 to more than 150 per year after 2010; this
trend has been reported in the literature.7 In April 2012, a three-
armed da Vinci Robotic System (Intuitive Surgical, Sunnyvale,
CA, USA) was installed in our department. Before the intro-
duction of this system, all RPs were performed as open RPs.
Our data show that men undergoing RP in Odense have
approximately the same erectile outcome as men reported in
other similar studies. Østby-Deglum et al20 reported erectile
recovery in 25% of men 1 to 6 years after robot-assisted lapa-
roscopic prostatectomy (RALP), Riikonen et al21 found that
25.7% could have intercourse with or without the use of PDE-5i
at 1 year after RALP, and Haglind et al22 reported 30% erectile
recovery 12 months after RALP and 25% recovery after open RP
irrespective of the surgical technique used. Our study compares
well with these studies in geographic area, ﬂow of operations, age,
preoperative PSA, BMI, and proportion with cardiovascular
comorbidity. Mandel et al23 reported a 33% recovery rate
regardless of surgical technique. A similar Danish study of 418
patients comparing RALP with open RP showed a 12-month
recovery rate of 28.9% among men after open RP and 36.3%
after RALP.24 The ideal follow-up is not 12 months, because
there are indications that the median time to return of inter-
course is 340 days.15
Our study showed that patients with a normal BMI, who were
younger than 60.5 years old, who had no cardiac disease, and
who underwent NSRP showed the greatest improvement in EF
during the ﬁrst 12 months. These features also were reported as
important predictors of EF after RP in other studies.15
We found that 30.1% of men who underwent NNSRP and
35.5% who underwent NSRP had ESI 12 months after RP.
There is no obvious explanation for this. However, because focus
on sexuality has been limited, preoperative EF has not been
systematically assessed. Therefore, we speculate that the most
suitable patients might not have been selected for NSRP. The
preoperative assessment of an RP candidate is the ﬁrst compul-
sory step in managing postoperative ED. This allows for correct
assessment of the potential risk of postsurgical ED, allowing the
surgeon to properly counsel the patient regarding the optimal
treatment, taking into account the patient’s wishes and expec-
tations, and performing an oncologically safe procedure.
In general, patients who undergo NNSRP are not considered
candidates for penile rehabilitation. In this cohort, we found a
larger proportion with ESI than anticipated among those who
underwent NNSPR. We recommend that a penile rehabilitation
program be offered to all patients who have EF before surgery,
regardless of the surgical technique used.
In the present study, postoperative care involved routine
follow-up. All patients had an outpatient appointment with their
surgeon 8 to 10 days after the operation to have their catheter
removed and to receive their histologic results. The patients
visited our clinic at 3, 6, 9, and 12 months after surgery.
The follow-up program included pelvic ﬂoor exercises for all
patients to promote urine continence recovery. Penile rehabili-
tation was not provided by standard instructions although this
has been recommended by an international expert panel.25
Table 3. Results of erectile function 12 months after radical
prostatectomy
ED 478 (67.9%)
1. Lack of interest in penile rehabilitation 155 (22%)
2. Did not resume sex life 26 (3.7%)
3. No further elaborated ED 56 (8.0%)
4. Sexually active but could not achieve ESI 241 (34.2%)
Using PDE-5i 30 (12.5%)
Using injection therapy 6 (2.5%)
Tried PDE-5i* 91 (37.8%)
Tried injection therapy* 4 (1.7%)
Referred for further sexual rehabilitation* 117 (48.5%)
ESI 226 (32.1%)
PDE-5i 90 (39.8%)
Injection therapy 18 (8.4%)
Using vacuum erect device 1 (0.4%)
Not stated 40 (17.7%)
ED ¼ erectile dysfunction; ESI ¼ self-reported erection sufﬁcient for
intercourse; injection therapy ¼ intracavernous injections of alprostadil;
PDE-5i ¼ phosphodiesterase type 5 inhibitor.
*Some patients might be in more than one group. No patient had been using
intraurethral agents and none had been offered penile prosthesis placement.
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Recommendations regarding the use of erectile aids were indi-
vidually determined depending on the surgeon’s assessment and
the patient’s choice. Since October 2013, we have offered sexual
counseling to all men with ED, including medical history, risk
factors, sexual history, sexual habits, and relationships. Because
there is no clear beneﬁt of one rehabilitation strategy over
another,26 the appropriate rehabilitation strategy is chosen based
on the patient’s choice and the surgeon’s objective information.
The limitations of our study include its retrospective
design, the mode of assessment used, and inadequate infor-
mation about preoperative sexual function. The strength of
the study is the number of patients and the fact that we
implemented a full 12-month follow-up. Mulhall7 described
10 methodologic requirements for studies reporting outcomes
after RP. The present study fulﬁlled seven of them. We did
not use validated questionnaires, had only 12 months of
follow-up data, and baseline data on EF were insufﬁcient for
calculation of the rates of men returning to their normal
function after RP.
CONCLUSION
We found that 32.1% of men who underwent RP subse-
quently had ESI and that half these men needed erectile aids. Age
older than 60.5 years, a high BMI, more comorbidities, and a
high ASA score predicted poor EF 12 months after RP. We
recommend counseling before surgery and a penile rehabilitation
program for this group of men.
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